Zynerba Pharmaceuticals stock price hits all-time high
Catalyst Pharmaceuticals (zynerbac) is up 12% in premarket trading on Friday, bringing its market cap to $19.5bn.The stock has been trending up since the start of the year.The company announced in January that it was launching a treatment for a rare and aggressive form of cancer called Rheumatoid Arthritis.The company has also announced it will…